EUVIMEDEUVIMED entdecken
Leitlinie

Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support

Carlos Alberto Valdes iD, Griffin Stinson iD, Omar M Sharaf, Fabian Jimenez Contreras, Ahmet Bilgili iD, Mustafa M Ahmed, Juan Vilaro, Alex M Parker, Mohammad A Z Al-Ani, Daniel Demos, Juan Aranda, Mark Bleiweis und 2 weitere

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery · 2024-01 · 19 (1) · 46-53

DOI: 10.1177/15569845231212157 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, online erschienen am 27.11.2023. Verfasst von Carlos Alberto Valdes und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Heart Transplantation, Heart-Assist Devices. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes. We sought to review our single-center experience with Impella 5.5 and compare outcomes based on support duration.

Methods

We retrospectively reviewed adult patients (≥18 years old) supported with Impella 5.5 at our institution (May 2020 to April 2023). Patients on prolonged support (>14 days) were compared with those supported for ≤14 days.

Results

There were 31 patients supported with Impella 5.5 including 14 (45.2%) supported >14 days. Median support duration for those on prolonged support was 43.5 (interquartile range [IQR] 25 to 63.5) days versus 8 (IQR 6, 13) days for those who were not ( P < 0.001). Overall, the device-related complication rate was 9.7% and did not differ between groups ( P = 0.08). Overall, 30-day postimplant survival was 71% and did not differ by support duration ( P = 0.2). In-hospital mortality was 32% and did not differ between cohorts ( P > 0.99). Among those surviving to explant ( n = 22), long-term strategy included bridge to durable ventricular assist device (18%, n = 4), cardiac transplant (55%, n = 12), and cardiac recovery (27%, n = 6).

Conclusions

High-risk patients with cardiogenic shock may be supported with Impella 5.5 beyond the FDA-approved duration without increased risk of complications or mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationHeart-Assist DevicesAdultUnited StatesHumansAdolescentRetrospective StudiesUnited States Food and Drug AdministrationTreatment OutcomeShock, Cardiogenic

Stichwörter der Autor:innen

Impellabridge to therapycardiogenic shockleft ventricular assist devicesmechanical circulatory support

Autor:innen und Institutionen

  • University of Florida, Gainesville, FL, USA.

ORCID-Profile: Carlos Alberto Valdes, Griffin Stinson, Ahmet Bilgili

Zitieren

APA

Valdes, C. A., Stinson, G., Sharaf, O. M., Jimenez Contreras, F., Bilgili, A., Ahmed, M. M., Vilaro, J., Parker, A. M., Al-Ani, M. A. Z., Demos, D., Aranda, J., Bleiweis, M., Beaver, T. M., & Jeng, E. I. (2024). Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 19(1), 46-53. https://doi.org/10.1177/15569845231212157

Vancouver

Valdes CA, Stinson G, Sharaf OM, Jimenez Contreras F, Bilgili A, Ahmed MM, et al. Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2024;19(1):46-53. doi:10.1177/15569845231212157

BibTeX
@article{Valdes2024,
  author = {Valdes, Carlos Alberto and Stinson, Griffin and Sharaf, Omar M and Jimenez Contreras, Fabian and Bilgili, Ahmet and Ahmed, Mustafa M and Vilaro, Juan and Parker, Alex M and Al-Ani, Mohammad A Z and Demos, Daniel and Aranda, Juan and Bleiweis, Mark and Beaver, Thomas M and Jeng, Eric I},
  title = {Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support},
  journal = {Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery},
  year = {2024},
  volume = {19},
  number = {1},
  pages = {46--53},
  doi = {10.1177/15569845231212157}
}
Kostenlos starten →